Larotrectinib: A Targeted Therapy for Solid Tumors.

Journal Article (Review;Journal Article)


Although neurotrophic tyrosine receptor kinase (NTRK) gene fusions are not common in most cancers, they are present in more than 90% of some rare tumors. The U.S. Food and Drug Administration has approved larotrectinib for patients with NTRK gene fusion-positive cancers that meet certain criteria. With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by cancer type in the future.


This article provides an overview of larotrectinib, a targeted therapy.


This article reviews clinical trial results and highlights implications for oncology nurses caring for patients taking larotrectinib.


Larotrectinib is an effective treatment option for some patients with NTRK gene fusion-positive cancers. Oncology nurses are key to educating patients on dosing, administration, side effects, and precautions.

Full Text

Duke Authors

Cited Authors

  • Mota-George, G; Schneider, SM

Published Date

  • April 2021

Published In

Volume / Issue

  • 25 / 2

Start / End Page

  • 181 - 187

PubMed ID

  • 33739345

Electronic International Standard Serial Number (EISSN)

  • 1538-067X

International Standard Serial Number (ISSN)

  • 1092-1095

Digital Object Identifier (DOI)

  • 10.1188/21.cjon.181-187


  • eng